The importance of ESR1 mutations in mBC development has not been discovered until 2013, when genomic sequencing of circulating tumor cells (CTC) in patients with metastatic disease allowed for its identification as a key factor of ET resistance (34–36). The gene discussed is ESR1; the disease is neoplasm.